You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.
Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.
Fluidigm's Helios mass cytometer and Hyperion imaging system will be bundled with De Novo's FCS Express 7 Flow software for suspension data analysis.
Researchers developed a highly multiplexed screen to quantify the co-expression of 351 molecules on the surfaces of millions of human B cells.
Fluidigm's mass cytometry and microfluidics research product sales were negatively impacted by the COVID-19 pandemic.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
Oslo-based InstruNor's systems will enable Fluidigm to offer fully automated, walkaway sample preparation for flow and mass cytometry.
Fourth quarter revenues of $32.4 million were in line with previously reported preliminary revenues and ahead of the Wall Street estimate of $30.8 million.
A federal judge granted IonPath's motion to dismiss portions of Fluidigm's suit but claims of direct infringement were untouched and will proceed.
Researchers used Fluidigm's Hyperion Imaging System to quantify 35 protein biomarkers and examine the phenotypes and organization of single cells within breast tumors.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.